Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus

Gian Domenico Sebastiani, Mauro Galeazzi, Angela Tincani, Jean Charles Piette, Josep Font, Flavio Allegri, Alessandro Mathieu, Josef Smolen, Enrique De Ramon Garrido, Antonio Fernandez-Nebro, Anna Jedryka-Goral, Chryssa Papasteriades, Gabriella Morozzi, Francesca Bellisai, Ornella De Pita, Roberto Marcolongo

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To test the prevalences and the clinical associations of anticardiolipin (aCL) and anti-β2GPI (aβ2GPI) antibodies in a large series of European patients with systemic lupus erythematosus (SLE). Methods: 574 SLE patients from 7 European countries were tested for aCL and aβ2GPI by ELISA methods. Results: aCL of IgG, IgM, and IgA isotypes were detected in 22.8%, 14%, and 13.9% of the patients, respectively. IgG and IgM aβ2GPI were detected in 20% of the patients. The presence of aCL was highly associated with the presence of aβ2GPI. Medium-high titer IgG aCL and aβ2GPI were associated with thrombosis, with similar sensitivity, specificity, and positive predictive value. When present at medium-high titer, IgG aCL were associated with thrombocytopenia, IgM aCL with hemolytic anemia, and cerebrovascular accidents, IgA aCL with livedo reticularis and Raynaud's phenomenon. Conclusions: aCL, when present at medium-high titer, are as important as aβ2GPI, as a risk factor for thrombosis. Medium-high titer aCL, but not aβ2GPI, are associated with other clinical features of the antiphospholipid syndrome.

Original languageEnglish
Pages (from-to)344-351
Number of pages8
JournalScandinavian Journal of Rheumatology
Volume28
Issue number6
Publication statusPublished - 1999

Keywords

  • aβGPI
  • aCL
  • Antiphospholipid syndrome
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Fingerprint Dive into the research topics of 'Anticardiolipin and anti-β2GPI antibodies in a large series of European patients with systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this